Degeneração Walleriana de origem vascular em ressonância magnética de paciente com paralisia supranuclear progressiva provável: fator etiológico ou associação fortuita? / Vascular Wallerian degeneration on magnetic resonance in a patient with probable progressive supranuclear palsy: aetiology or casual link?

Progressive supranuclear palsy (PSP) is one of the most important causes of parkinsonism non responsive to therapy. Vascular parkinsonism is not uncommon. However, the cause-effect relationship between them is uncertain. We report on a 65 year old man with probable PSP who developed the clinical features of the disease after a ischaemic stroke. Magnetic resonance imaging disclosed a corticospinal tract Wallerian degeneration. There is not such an observation in the literature about this possible correlation.

Paralisia supranuclear progressiva (PSP) é uma das principais causas de parkinsonismo-plus não responsivo a terapia. A ocorrência de doença cerebrovascular associada a parkinsonismo não é infreqüente, no entanto é difícil estabelecer a relação causa-efeito entre ambas. Relatamos o caso de um paciente de 65 anos com PSP provável iniciada após infarto cerebral, em que a imagem por ressonância magnética evidenciou sinais de degeneração walleriana do trato córtico-espinhal. Não há relato na literatura pesquisada sobre esta possível correlação.

Immunization against hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 MCG)

A previous seroepidemiological study in the rural zone of Vargem Alta (ES) SouthEast of Brazil, showed a prevalence of up to 9 of hepatitis B surface antigen (HBsAg) in some areas. One hundred susceptible children aging 1 to 5 years old were selected and immunized with a recombinant DNA hepatitis B vaccine (Smith-Kline 20 mcg) using the 0-1-6 months vaccination schedule. Blood samples were collected at the time of the first vaccine dose (month 0) in order to confirm susceptible individuals and 1,3,6 and 8 months after the first dose, to evaluate the antibody response. Our results showed that two and five months after the second dose, 79 and 88 of children seroconverted respectively, reaching 97 after the third dose. The levels of anti-HBs were calculated in milli International Units/ml (mIU/ml) and demonstrated the markedly increase of protective levels of antibodies after the third dose. These data showed a good immunogenicity of the DNA recombinant hepatitis B vaccine when administered in children of endemic areas.